Author details

Full Name

Justin M Balko

Affiliation

ORCID

Career Start Year

2006

Papers

145

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36926262	Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations.		2023
37791898	NKG2A is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple Negative Breast Cancer.		2023
37556775	Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.	J Clin Oncol	2023
37470280	Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities.		2023
36585450	Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.	Nat Cancer	2023
37025902	Convolutional neural network for biomarker discovery for triple negative breast cancer with RNA sequencing data.	Heliyon	2023
36648402	Corticosteroids and Cancer Immunotherapy.		2023
37146128	STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy.		2023
36895920	Peripheral T-cell receptor repertoire dynamics in small cell lung cancer.	Transl Lung Cancer Res	2023
36868223	T cell dynamism and immune-related adverse events.		2023
37059102	No rest for the wicked: Tumor cell senescence reshapes the immune microenvironment.		2023
36472455	Interactive network-based clustering and investigation of multimorbidity association matrices with associationSubgraphs.	Bioinformatics	2023
36680880	Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.		2023
35082367	Immune-checkpoint inhibitors: long-term implications of toxicity.	Nature Reviews Clinical Oncology	2022
35590189	Primed for toxicity: CD4+ TÂ cells and immune checkpoint inhibitors.	Med	2022
36304942	Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer.	Cancer Res Commun	2022
35561311	Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer.	Cancer Immunol Res	2022
36385524	T cells specific for Î±-myosin drive immunotherapy-related myocarditis.	Nature	2022
35850776	Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer.	Breast Cancer Research	2022
35296095	Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response.	Frontiers in Immunology	2022
34899704	Pharmacological Activation of cGAS for Cancer Immunotherapy.	Frontiers in Immunology	2021
34126013	RNA-Sequencing Reveals a Distinct Transcriptomic Signature for Giant Cell Myocarditis and Identifies Novel Druggable Targets.	Circ Res	2021
33475287	Triple-Negative Breast Cancer: Breast Tumors With an Identity Crisis.	Cancer J	2021
33958486	Progesterone promotes immunomodulation and tumor development in the murine mammary gland.	J Immunother Cancer	2021
33843927	Automated Dissection Protocol for Tumor Enrichment in Low Tumor Content Tissues.	Journal of Visualized Experiments	2021
34322780	Breast cancer resistance mechanisms: challenges to immunotherapy.	Breast Cancer Research and Treatment	2021
34315723	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer.	Clin Cancer Res	2021
33257470	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.	Cancer Discovery	2021
33189789	Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.	Journal of Controlled Release	2021
34629099	Artificial image objects for classification of breast cancer biomarkers with transcriptome sequencing data and convolutional neural network algorithms.	Breast Cancer Res	2021
34390291	Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer Center.	Oncologist	2021
34725325	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes.	Nat Commun	2021
32995820	Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial.	medRxiv	2020
31851488	Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies.	ACS Nano	2020
32017708	A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.	Journal of Clinical Investigation	2020
32129476	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.	J Pathol	2020
32350001	Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy.	Cancer Immunology Research	2020
32169869	Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.	Journal for ImmunoTherapy of Cancer	2020
32391191	Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancer.	OncoImmunology	2020
32826327	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.	Clin Cancer Res	2020
32543711	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy.	Br J Clin Pharmacol	2020
32758477	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research.	Lancet Oncology, The	2020
32591446	Correction: Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.	Journal of Biological Chemistry	2020
32634121	MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC.	JCI Insight	2020
32511636	Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer.		2020
33062958	MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression.	Cancer Drug Resistance	2020
33274924	Correction to "Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies".	ACS Nano	2020
30770371	Correction: Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer.	Cancer Res	2019
31602395	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.	NPJ Breast Cancer	2019
31552290	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.	NPJ Breast Cancer	2019